Ha Tay Pharmaceutical JSC Past Earnings Performance
Past criteria checks 2/6
Ha Tay Pharmaceutical JSC has been growing earnings at an average annual rate of 1.1%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been declining at an average rate of 0.7% per year. Ha Tay Pharmaceutical JSC's return on equity is 6.6%, and it has net margins of 3.4%.
Key information
1.1%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | -0.7% |
| Return on equity | 6.6% |
| Net Margin | 3.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ha Tay Pharmaceutical JSC makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,952,464 | 66,840 | 120,547 | 0 |
| 31 Mar 24 | 1,975,884 | 75,948 | 112,331 | 0 |
| 31 Dec 23 | 1,999,304 | 85,056 | 104,115 | 0 |
| 30 Sep 23 | 2,059,424 | 104,458 | 91,405 | 0 |
| 31 Mar 23 | 1,928,912 | 102,908 | 88,306 | 0 |
| 31 Dec 22 | 1,837,395 | 95,211 | 84,806 | 0 |
| 30 Sep 22 | 1,749,385 | 79,139 | 93,034 | 0 |
| 30 Jun 22 | 1,582,890 | 64,971 | 88,844 | 0 |
| 31 Mar 22 | 1,637,143 | 65,703 | 92,420 | 0 |
| 31 Dec 21 | 1,609,364 | 67,946 | 91,953 | 0 |
| 30 Sep 21 | 1,781,911 | 72,148 | 102,830 | 0 |
| 30 Jun 21 | 1,929,218 | 82,433 | 104,418 | 0 |
| 31 Mar 21 | 1,867,492 | 81,610 | 109,674 | 0 |
| 31 Dec 20 | 2,006,475 | 92,047 | 129,633 | 0 |
| 30 Sep 20 | 1,936,713 | 89,424 | 138,346 | 0 |
| 30 Jun 20 | 2,053,240 | 86,717 | 159,561 | 0 |
| 31 Mar 20 | 2,159,851 | 93,991 | 165,255 | 0 |
| 31 Dec 19 | 2,042,235 | 86,233 | 153,241 | 0 |
| 30 Sep 19 | 1,916,672 | 89,508 | 152,697 | 0 |
| 30 Jun 19 | 1,842,798 | 44,570 | 145,041 | 0 |
| 31 Mar 19 | 1,723,270 | 85,409 | 145,450 | 0 |
| 31 Dec 18 | 1,705,345 | 81,080 | 152,848 | 0 |
| 30 Sep 18 | 1,657,794 | 86,566 | 143,174 | 0 |
| 30 Jun 18 | 1,582,946 | 82,939 | 143,238 | 0 |
| 31 Mar 18 | 1,531,630 | 77,538 | 141,118 | 0 |
| 31 Dec 17 | 1,480,315 | 72,137 | 138,999 | 0 |
| 30 Sep 17 | 1,416,999 | 71,387 | 128,636 | 0 |
| 31 Mar 17 | 1,264,793 | 59,468 | 118,433 | 0 |
| 31 Dec 16 | 1,205,441 | 53,798 | 114,835 | 0 |
| 30 Sep 16 | 1,105,295 | 37,833 | 116,937 | 0 |
| 31 Mar 16 | 999,551 | 35,590 | 109,021 | 0 |
| 31 Dec 15 | 940,572 | 34,354 | 101,038 | 0 |
| 30 Sep 15 | 907,669 | 25,444 | 100,694 | 0 |
| 30 Jun 15 | 852,252 | 26,252 | 99,070 | 0 |
| 31 Mar 15 | 820,662 | 27,370 | 92,003 | 0 |
| 31 Dec 14 | 820,054 | 26,298 | 91,756 | 0 |
| 30 Sep 14 | 821,573 | 36,769 | 85,979 | 0 |
| 30 Jun 14 | 770,589 | 20,954 | 82,663 | 0 |
| 31 Mar 14 | 788,281 | 29,558 | 86,552 | 0 |
| 01 Jan 14 | 742,982 | 26,761 | 80,099 | 0 |
Quality Earnings: DHT has high quality earnings.
Growing Profit Margin: DHT's current net profit margins (3.4%) are lower than last year (5.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DHT's earnings have grown by 1.1% per year over the past 5 years.
Accelerating Growth: DHT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DHT had negative earnings growth (-35.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13%).
Return on Equity
High ROE: DHT's Return on Equity (6.6%) is considered low.